REMEGEN - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

nor makes any representation as to its completeness and expressly disclaims any liability arising out of or in reliance upon the whole or any part of the contents of this announcement. We are not responsible for any losses caused by the content.

RemeGen Co., Ltd.*

Rongchang Biopharmaceutical (Yantai) Co., Ltd. (a joint stock limited company incorporated in the People's Republic of China) (Stock code: 9995)

Overseas regulatory announcement

This announcement is made by Rongchang Biopharmaceuticals in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. (Yantai) Co., Ltd. (the "Company").

The announcement published by the Company on the website of the Shanghai Stock Exchange is set out below for reference only.

By order of the board of directors Rongchang Biopharmaceutical (Yantai) Co., Ltd.

Chairman and Executive Director Mr. Wang Weidong

Yantai, China July 19, 2026

As at the date of this announcement, members of the Board of Directors include executive directors Mr. Wang Weidong, Dr. Fang Jianmin, and Wen Qingkaixian. Sheng, Ms. Fang Yi and Mr. Wang Yuxiao; non-executive director Dr. Wang Liqiang; and independent non-executive director Song Xiliang

Mr. Huang Guobin and Mr. Chen Yunjin.

*For identification only

Securities code: 688331 Securities abbreviation: Rongchang Biotechnology Announcement number: 2026-032

Hong Kong stock code: 09995 Hong Kong stock abbreviation: Rongchang Biotechnology

Rongchang Biopharmaceutical (Yantai) Co., Ltd.

Announcement of Resolutions of the Second Meeting of the Third Board of Directors

The board of directors and all directors of the company guarantee that the contents of this announcement do not contain any false records or misleading statements.

statements or major omissions, and shall bear legal responsibility for the authenticity, accuracy and completeness of its contents in accordance with the law.

1. Convening of board of directors meetings

The third session of the Board of Directors of Rongchang Biopharmaceutical (Yantai) Co., Ltd. (hereinafter referred to as the "Company") The second meeting was held on July 19, 2026 in the company's conference room via on-site communication. this meeting

It was presided over by Mr. Wang Weidong, the chairman of the board of directors. There were 9 directors who should be present, but 9 directors were actually present. The meeting was held

The procedures for convening meetings are in compliance with the Company Law of the People's Republic of China and other laws and regulations, normative documents and the "Rongsheng Law".

The relevant provisions of the Articles of Association of Chang Biopharmaceutical (Yantai) Co., Ltd. (hereinafter referred to as the "Articles of Association"),

The resolutions reached at the meeting are legal and valid.

2. Review status of board of directors meeting

(1) Consideration and approval of the "Regulations on the First Repurchase of the Company's Shares through Centralized Bidding Transactions in 2026"

motion of the case

Based on confidence in the company's future development and recognition of the company's value, promote the company's stability, health, and

To achieve sustainable development, the board of directors agrees that the company can trade through the Shanghai Stock Exchange with its own funds and/or self-raised funds.

Yi Systems repurchased some of the company's issued RMB ordinary shares (A shares) through centralized bidding transactions. votes. The repurchased shares will be used for employee stock ownership plans or equity incentives at an appropriate time in the future. repurchase funds

The total amount shall not be less than RMB 25 million (inclusive) and not exceed RMB 50 million (inclusive), the same

At that time, the company's management was authorized to handle all matters related to the share repurchase.

After voting by the directors present at the meeting, there were 9 votes in favor, 0 votes against, and 0 abstentions. Agree votes accounted for

100% of the directors.

For details, please refer to the "Rongsheng Company" disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on the same day.

Chang Biopharmaceutical (Yantai) Co., Ltd.’s first repurchase through centralized bidding transaction in 2026

Plan for the Company’s Shares” (Announcement No.: 2026-033).

Announcement is hereby made.

Rongchang Biopharmaceutical (Yantai) Co., Ltd. Board of Directors

July 20, 2026